Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab

@article{Bakri2006RapidRO,
  title={Rapid regression of disc neovascularization in a patient with proliferative diabetic retinopathy following adjunctive intravitreal bevacizumab},
  author={Sophie J. Bakri and Mark J. Donaldson and Thomas P Link},
  journal={Eye},
  year={2006},
  volume={20},
  pages={1474-1475}
}
Bevacizumab (Avastin, Genentech Inc., San Francisco, CA, USA) is a recombinant humanized monoclonal IgG1 antibody that inhibits human vascular endothelial growth factor (VEGF). It has been administered intravitreally in VEGF-mediated diseases such as choroidal neovascularization and central retinal vein occlusion. VEGF plays a major role in mediating… CONTINUE READING